Literature DB >> 7795598

The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13.

B Brais1, Y G Xie, M Sanson, K Morgan, J Weissenbach, A D Korczyn, S C Blumen, M Fardeau, F M Tomé, J P Bouchard.   

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant muscular dystrophy which presents typically after the age of 50 with progressive eyelid drooping and an increasing difficulty in swallowing. Though OPMD has a world-wide incidence, it is more common in the French Canadian population. We have identified a homogeneous group of families and studied 166 polymorphic markers as part of a genome search before establishing linkage to chromosome 14. We determined that the OPMD locus maps to a less than 5 cM region of chromosome 14q11.2-q13. The maximum two-point lod score in three French Canadian families of 14.73 (theta = 0.03) was obtained for an intronic cardiac beta myosin heavy chain gene (MYH7) marker. The regional localization for the OPMD locus raises the intriguing possibility that either the cardiac alpha or beta myosin heavy chain genes may play a role in this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795598     DOI: 10.1093/hmg/4.3.429

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  14 in total

1.  Unique PABPN1 gene mutation in a large Bulgarian family with OPMD.

Authors:  V Mihaylova; T Müller; I Petrova; I Tournev; S Cherninkova; M C Walter; M Deschauer
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

2.  No evidence for heterogeneity in oculopharyngeal muscular dystrophy.

Authors:  W Kress; B Halliger-Keller; T Grimm; H Porschke; A Engelhardt; H H Goebel; B Müller-Mysok
Journal:  J Med Genet       Date:  1998-07       Impact factor: 6.318

3.  Muscular involvement assessed by MRI correlates to motor function measurement values in oculopharyngeal muscular dystrophy.

Authors:  Arne Fischmann; Monika Gloor; Susanne Fasler; Tanja Haas; Rachele Rodoni Wetzel; Oliver Bieri; Stephan Wetzel; Karl Heinimann; Klaus Scheffler; Dirk Fischer
Journal:  J Neurol       Date:  2011-02-22       Impact factor: 4.849

4.  Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis.

Authors:  Carol Dobson-Stone; Antonio Velayos-Baeza; An Jansen; Frederick Andermann; François Dubeau; Francine Robert; Anne Summers; Anthony E Lang; Sylvain Chouinard; Adrian Danek; Eva Andermann; Anthony P Monaco
Journal:  Neurogenetics       Date:  2005-09-28       Impact factor: 2.660

5.  Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.

Authors:  Katherine E Vest; Brittany L Phillips; Ayan Banerjee; Luciano H Apponi; Eric B Dammer; Weiting Xu; Dinghai Zheng; Julia Yu; Bin Tian; Grace K Pavlath; Anita H Corbett
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

6.  Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Authors:  P N Tonin; A M Mes-Masson; P A Futreal; K Morgan; M Mahon; W D Foulkes; D E Cole; D Provencher; P Ghadirian; S A Narod
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

Review 7.  Oculopharyngeal muscular dystrophy: a polyalanine myopathy.

Authors:  Bernard Brais
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

8.  Valproic acid is protective in cellular and worm models of oculopharyngeal muscular dystrophy.

Authors:  Aida Abu-Baker; Alex Parker; Siriram Ramalingam; Janet Laganiere; Bernard Brais; Christian Neri; Patrick Dion; Guy Rouleau
Journal:  Neurology       Date:  2018-07-13       Impact factor: 9.910

Review 9.  Genome engineering: a new approach to gene therapy for neuromuscular disorders.

Authors:  Christopher E Nelson; Jacqueline N Robinson-Hamm; Charles A Gersbach
Journal:  Nat Rev Neurol       Date:  2017-09-29       Impact factor: 42.937

10.  Polyalanine-independent conformational conversion of nuclear poly(A)-binding protein 1 (PABPN1).

Authors:  Reno Winter; Uwe Kühn; Gerd Hause; Elisabeth Schwarz
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.